Understanding the Changing Regulatory Landscape of Biogenerics/Biosimilars/Follow-on-Biologics and T
|Event Date/Time: Aug 28, 2007||End Date/Time: Aug 28, 2007|
1) What are the differences between biogenerics, Biosimilars and follow-on-biologics?
2) What are the current regulations of FOBs in the United States?
3) How will upcoming regulations impact generic and pharmaceutical companies?
4) What is Bioequivalence and Interchangeability and how do they relate to FOBs and Innovator Drugs?
5) What challenges will the U.S. face, if FOB regulation is approved?
6) Will FOBs hinder innovation and interfere with intellectual property and patents?